A61K 38/22
Hormones
Official title: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)
A61K38/22 (Hormones) appears on 6,176 US grants and 10,458 published applications in this corpus.
Search patents in A61K- Granted patents
- 6,176
- Published applications
- 10,458
- Assignees
- 3,087
- Inventors
- 14,172
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 3 | 0 |
| 1977 | 5 | 0 |
| 1978 | 3 | 0 |
| 1979 | 6 | 0 |
| 1980 | 4 | 0 |
| 1981 | 2 | 0 |
| 1982 | 5 | 0 |
| 1983 | 4 | 0 |
| 1984 | 4 | 0 |
| 1985 | 7 | 0 |
| 1986 | 11 | 0 |
| 1987 | 15 | 0 |
| 1988 | 17 | 0 |
| 1989 | 23 | 0 |
| 1990 | 20 | 0 |
| 1991 | 44 | 0 |
| 1992 | 51 | 0 |
| 1993 | 42 | 0 |
| 1994 | 33 | 0 |
| 1995 | 59 | 0 |
| 1996 | 64 | 0 |
| 1997 | 130 | 0 |
| 1998 | 148 | 0 |
| 1999 | 147 | 0 |
| 2000 | 104 | 0 |
| 2001 | 104 | 64 |
| 2002 | 115 | 208 |
| 2003 | 117 | 289 |
| 2004 | 103 | 314 |
| 2005 | 95 | 295 |
| 2006 | 134 | 373 |
| 2007 | 99 | 345 |
| 2008 | 111 | 361 |
| 2009 | 108 | 379 |
| 2010 | 173 | 415 |
| 2011 | 165 | 382 |
| 2012 | 219 | 371 |
| 2013 | 220 | 452 |
| 2014 | 288 | 503 |
| 2015 | 290 | 528 |
| 2016 | 300 | 522 |
| 2017 | 313 | 523 |
| 2018 | 324 | 455 |
| 2019 | 295 | 535 |
| 2020 | 284 | 506 |
| 2021 | 304 | 471 |
| 2022 | 218 | 467 |
| 2023 | 236 | 439 |
| 2024 | 213 | 488 |
| 2025 | 241 | 446 |
| 2026 | 156 | 327 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- A61K 38/28Insulins2,093
- A61K 38/26Glucagons1,279
- A61K 38/27Growth hormone [gh], i.e. somatotropin808
- A61K 38/30Insulin-like growth factors, i.e. somatomedins557
- A61K 38/29Parathyroid hormone, i.e. parathormone396
- A61K 38/23Calcitonins301
- A61K 38/24Follicle-stimulating hormone [fsh]294
- A61K 38/31Somatostatins272
All 23 subgroupsShow fewer
- A61K 38/2278Vasoactive intestinal peptide [vip]228
- A61K 38/25Growth hormone-releasing factor [gh-rf], i.e. somatoliberin228
- A61K 38/2264Obesity-gene products175
- A61K 38/2242Atrial natriuretic factor complex: atriopeptins, atrial natriuretic protein [anp]156
- A61K 38/2292Thymosin104
- A61K 38/225Calcitonin gene related peptide96
- A61K 38/2221Relaxins94
- A61K 38/2235Secretins67
- A61K 38/2257Prolactin64
- A61K 38/2207Gastrins62
- A61K 38/2271Neuropeptide y57
- A61K 38/2228Corticotropin releasing factor [crf]47
- A61K 38/2285Endothelin, vasoactive intestinal contractor [vic]27
- A61K 38/32Thymopoietins13
- A61K 38/2214Motilins12
Recent patents
- Protein with anti-inflammatory properties6 Oct 2026US 12,753,214 B2Revolo Biotherapeutics Limited
- Methods of treating Prader Willi Syndrome and conditions associated with low basal metabolic rate or hyperphagia using a KATP channel opener29 Sep 2026US 12,746,244 B2Sedogen LLC
- Probiotics compositions and method of using the same to enhance growth and social function in children29 Sep 2026US 12,746,262 B2The General Hospital Corporation
- Probiotics compositions and method of using the same to enhance growth and social function in children29 Sep 2026US 12,746,264 B2The General Hospital Corporation
- Implants for release of lipophilic or amphiphilic pharmaceutical substances29 Sep 2026US 12,746,275 B2ReacX Pharmaceuticals, Inc.
- Method to induce exfoliation of cells and/or tissue fragments for enhanced cytopathologic cell collection8 Oct 2026US 2026/0306077 A1Adenocyte Ltd.
- Exogenous protein-expressing microorganism and use thereof8 Oct 2026US 2026/0306586 A1Medytox Inc.
- Fgf21 compound / glp-1r agonist combinations with optimized activity ratio8 Oct 2026US 2026/0306587 A1Sanofi
- Compositions and uses of glp-1-gip receptor agonists8 Oct 2026US 2026/0306588 A1Maison Blaise Labs, LLC
- Alk7 combination treatments8 Oct 2026US 2026/0306628 A1
Most cited
By later US patents
- System and method for initiating and maintaining continuous, long-term control of a concentration of a substance in a patient using a feedback or model-based controller coupled to a single-needle or multi-needle intradermal (ID) delivery device968US 7,060,059 B2Becton, Dickinson and Company · 2006
- Preparation of particles for inhalation553US 5,985,309 AMassachusetts Institute of Technology · 1999
- Particles incorporating surfactants for pulmonary drug delivery537US 5,855,913 AMassachusetts Instite of Technology · 1999
- Method and apparatus for glucose control and insulin dosing for diabetics455US 7,651,845 B2The Regents of the University of California · 2010
- Engineered nucleic acids and methods of use thereof372US 8,822,663 B2Moderna Therapeutics, Inc. · 2014